GSK plc American Depositary Shares (Each representing two Ordinary Shares)$51.48MMM · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $24.95B | $24.57B | $24.61B | $26.16B | $35.35B | $32.18B | $32.14B | $32.77B |
| Cost of Revenue | $14.99B | $14.45B | $14.98B | $15.85B | $18.80B | $16.61B | $17.14B | $16.68B |
| Research & Development | — | $700.00M | $700.00M | $800.00M | $1.20B | $1.10B | $1.25B | $1.25B |
| Selling, General & Administrative | $4.00B | $4.22B | $19.20B | $7.23B | $7.20B | $6.93B | $7.03B | $7.60B |
| Operating Expenses | $20.32B | $19.75B | $35.30B | $21.79B | $27.99B | $25.02B | $25.96B | $25.56B |
| Operating Income | $4.63B | $4.82B | -$10.69B | $4.37B | $7.37B | $7.16B | $6.17B | $7.21B |
| Interest Expense | $448.00M | $472.00M | $942.00M | $462.00M | $488.00M | $529.00M | $448.00M | $350.00M |
| Other Income / (Expense) | -$416.00M | -$3.00M | -$582.00M | -$165.00M | -$165.00M | -$366.00M | -$531.00M | -$207.00M |
| Income Before Taxes | $4.21B | $4.82B | -$11.27B | $4.20B | $7.20B | $6.79B | $5.71B | $7.00B |
| Provision for Income Taxes | $1.00B | $804.00M | -$2.87B | $188.00M | $1.28B | $1.34B | $1.11B | $1.64B |
| Net Income | $3.25B | $4.17B | -$7.00B | $5.78B | $5.92B | $5.45B | $4.52B | $5.35B |
| Basic EPS | $6.05 | $7.58 | -$12.63 | $10.21 | $10.23 | $9.43 | $7.83 | $9.09 |
| Diluted EPS | $6.00 | $7.55 | -$12.63 | $10.18 | $10.12 | $9.36 | $7.72 | $8.89 |
| Basic Shares Outstanding | 537.40M | 550.80M | 553.90M | 566.00M | 579.00M | 577.60M | 577.00M | 588.50M |
| Diluted Shares Outstanding | 541.30M | 552.40M | 553.90M | 567.60M | 585.30M | 582.20M | 585.10M | 602.00M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $8.95 | $8.86 | $9.03 | 6 | ↑6 ↓0 |
| Dec 2027 | $9.70 | $9.39 | $10.05 | 7 | ↑7 ↓0 |
| Dec 2028 | $10.07 | $9.79 | $10.32 | 3 | ↑2 ↓0 |
| Dec 2029 | $10.63 | $10.63 | $10.63 | 1 | ↑1 ↓0 |
